2026-03-162026-03-162024-10-03SOUZA, Hugo Gabriel Carvalho. Uso terapêutico do canabidiol para tratamento da doença de alzheimer. Orientador: Luís Antônio Loureiro Maués. 2024. 20 f. Trabalho de Conclusão de Curso (Bacharelado em Medicina) - Faculdade de Medicina, Campus Universitário de Altamira, Universidade Federal do Pará, Altamira, 2024. Disponível em: https://bdm.ufpa.br/handle/prefix/9356. Acesso em:.https://bdm.ufpa.br/handle/prefix/9356Alzheimer's disease (AD) is the most common dementia in the world, it is estimated that in Brazil there are 1.2 million and 35.6 million people in the world with the disease. It occurs due to the accumulation of amyloid-β peptide (Aβ) with the consequent formation of amyloid plaques in the brain and aggregation of tau protein, which forms intracellular neurofibrillary tangles, especially in the medial temporal lobe and neocortical structures. This study aims to describe the possible mechanisms of action of cannabidiol (CBD), which exert an effect on the pathoetiological cascade of Alzheimer's disease, being able to provide a certain control over this pathology, being a possible alternative drug to be used in patients with AD, especially those refractory to conventional treatment. This work was carried out using the narrative literature review model and the search for the bibliographic collection was carried out in the Pubmed, MEDLINE and LILACS databases, with the help of EndNote Software. The most relevant articles were extracted from the aforementioned bases to satisfy the objectives of this work with subsequent critical analysis of them. Several literatures have shown promising results regarding the effectiveness of cannabidiol as an alternative to the treatment of Alzheimer's. In short, CBD has several mechanisms of action capable of attenuating the pathophysiological cascade of AD, through multiple pathways, with a supposed reduction in oxidative stress, neuroinflammation, neurodegeneration , reactive gliosis, in addition, it also acts by reducing the production and aggregation of Aβ and the production of intracellular fibrillar tangles, main characteristics of the pathophysiology of Alzheimer's. In addition, several clinical trials carried out in countries where the medicinal use of cannabis is regulated have revealed considerable improvements in the prognosis of patients undergoing treatment with CBD. In this sense, it is important that this and other studies on the subject gain greater visibility in the medical community and in Brazilian civil society, aiming to increase the number of professionals willing to use alternative treatment with CBD, in addition to removing the stigma rooted in the vast majority of the population regarding medical marijuana.Acesso AbertoAlzheimerβ-amiloideProteína tauCanabidiolAlzheimer's,β-amyloidTau proteinCannabidiolCNPQ::CIENCIAS DA SAUDE::MEDICINATrabalho de Curso - Graduação - MonografiaAttribution-NonCommercial-NoDerivs 3.0 Brazil